Lamotrigine blocks NMDA receptor-initiated arachidonic acid signalling in rat brain: implications for its efficacy in bipolar disorder

Abstract

An upregulated brain arachidonic acid (AA) cascade and a hyperglutamatergic state characterize bipolar disorder (BD). Lamotrigine (LTG), a mood stabilizer approved for treating BD, is reported to interfere with glutamatergic neurotransmission involving N-methyl-D-aspartate receptors (NMDARs). NMDARs allow extracellular calcium into the cell, thereby stimulating calcium-dependent cytosolic phospholipase A2 (cPLA2) to release arachidonic acid (AA) from membrane phospholipid. We hypothesized that LTG, like other approved mood stabilizers, would reduce NMDAR-mediated AA signaling in rat brain. An acute subconvulsant dose of NMDA (25 mg/kg) or saline was administered intraperitoneally to unanesthetized rats that had been treated p.o. daily for 42 days with vehicle or a therapeutically relevant dose of LTG (10 mg/kg/.d). Regional brain AA incorporation coefficients k* and rates Jin, AA signals, were measured using quantitative autoradiography after intravenous [1-14C]AA infusion, as were other AA cascade markers. In chronic vehicle-treated rats, acute NMDA compared to saline increased k* and Jin in widespread regions of the brain, as well as prostaglandin (PG)E2 and thromboxane B2 concentrations. Chronic LTG treatment compared to vehicle reduced brain cyclooxygenase (COX) activity, PGE2 concentration, and DNA binding activity of the COX-2 transcription factor, NF-κB. Pretreatment with chronic LTG blocked the acute NMDA effects on AA cascade markers. In summary, chronic LTG like other mood stabilizers blocks NMDA-mediated signaling involving the AA metabolic cascade. Since markers of the AA cascade and of NMDAR signaling are up-regulated in the postmortem BD brain, mood stabilizers generally may be effective in BD by dampening NMDAR signalling and the AA cascade.

Chronic valproate treatment blocks D2-like receptor-mediated brain signaling via arachidonic acid in rats

“…A similar reduction in plasma unesterified fatty acids has been found with other mood stabilizers and antipsychotics used to treat BD, such as lamotrigine, olanzapine and clozapine (Ramadan et al, 2011; Cheon et al, unpublished observation) suggesting a common peripheral effect of these drugs. The decrease in plasma unesterified fatty acids may be due to (i) reduced liver secretion of lipoprotein-bound esterified fatty acids, the main source of unesterified fatty acids in plasma, or (ii) reduced release of unesterified fatty acids from adipose tissue by lipases.…”

A Simple and Highly Sensitive Quantitation of Eicosanoids in Biological Samples Using Nano-flow Liquid Chromatography/ Mass Spectrometry

“…Moreover, the endogenous concentration observed in this experiment was almost equivalent to the values in other reports. 35 Taken together, this study demonstrated the feasibility of this method for sample preparation and quantitation.…”

Pharmacological evidence for the involvement of the NMDA receptor and nitric oxide pathway in the antidepressant-like effect of lamotrigine in the mouse forced swimming test

“…Surprisingly, only a small number of experiments reported the interaction of lamotrigine with NMDA receptors. For instance, a novel study reported that lamotrigine is effective in treatment of bipolar disorder through blockade of NMDA receptors [66]. Although the blockade of neuronal voltage-dependent sodium (n = 8).…”